论文部分内容阅读
Rosiglitazone is clinically used to treat insulin resistance.However,its long-term administration will increase the incidence of cardiovascular side effects.[1] Given the beneficial effects of nitric oxide(NO)on endothelial function as an anti-hypertensive agent[2],we are motivated to synthesize hybrid compounds of rosiglitazone bearing nitrate-or diazeniumdiolate-based NO donating moieties.